Evvy Raises $40M Series B for Women's Health Precision Medicine

Evvy Closes $40M Series B

Evvy, a New York-based precision medicine company for women's health, has raised $40 million in Series B funding. The round was led by Catalio Capital Management.

What Evvy Does

Evvy is built around what it describes as the world's largest proprietary, clinical-grade dataset on the vaginal microbiome and women's health outcomes. Its at-home test uses CLIA-certified, NYS CLEP-approved metagenomic sequencing to screen for more than 700 bacteria and fungi. Results are ordered and interpreted by licensed clinicians and paired with personalized prescription treatment and longitudinal biomarker tracking.

The platform serves over 100,000 patients and 3,000 practitioners in the United States. It has generated 13 peer-reviewed publications and powers EvvyAI, a machine-learning advisor the company is extending from vaginal health into fertility care.

Funding Details

• Round: Series B
• Amount: $40,000,000 USD
• Date: September 15, 2026
• Lead Investor: Catalio Capital Management
• Participating Investors: General Catalyst, Ingeborg Investments, Muse Capital, Labcorp Venture Fund, BBG Ventures, Amboy Street Ventures, Rethink Impact, Alumni Ventures, Left Lane Capital, Foreground Capital, Flywheel Ventures

Acquisition Perspective

Evvy combines a proprietary clinical-grade dataset, a growing patient and practitioner network, and an AI advisor in EvvyAI. The Series B funding, led by Catalio Capital Management with participation from a broad syndicate including Labcorp Venture Fund, positions the company to expand its precision medicine platform and extend into fertility care.